Research ExplorerPublicationsHigh Ep-CAM expression is associated with poor prognosis in ...

High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer.

Standard

High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. / Spizzo, Gilbert; Went, Philip; Dirnhofer, Stephan; Obrist, Peter; Simon, Ronald; Spichtin, Hanspeter; Maurer, Robert; Metzger, Urs; von Castelberg, Brida; Bart, Rahel; Stopatschinskaya, Shanna; Köchli, Ossi Robert; Haas, Philip; Mross, Friedrich; Zuber, Markus; Dietrich, Holger; Bischoff, Susanne; Mirlacher, Martina; Sauter, Guido; Gastl, Guenther.

In: BREAST CANCER RES TR, Vol. 86, No. 3, 3, 2004, p. 207-213.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Spizzo, G, Went, P, Dirnhofer, S, Obrist, P, Simon, R, Spichtin, H, Maurer, R, Metzger, U, von Castelberg, B, Bart, R, Stopatschinskaya, S, Köchli, OR, Haas, P, Mross, F, Zuber, M, Dietrich, H, Bischoff, S, Mirlacher, M, Sauter, G & Gastl, G 2004, 'High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer.', BREAST CANCER RES TR, vol. 86, no. 3, 3, pp. 207-213. <http://www.ncbi.nlm.nih.gov/pubmed/15567937?dopt=Citation>

APA

Spizzo, G., Went, P., Dirnhofer, S., Obrist, P., Simon, R., Spichtin, H., Maurer, R., Metzger, U., von Castelberg, B., Bart, R., Stopatschinskaya, S., Köchli, O. R., Haas, P., Mross, F., Zuber, M., Dietrich, H., Bischoff, S., Mirlacher, M., Sauter, G., & Gastl, G. (2004). High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. BREAST CANCER RES TR, 86(3), 207-213. [3]. http://www.ncbi.nlm.nih.gov/pubmed/15567937?dopt=Citation

Vancouver

Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H et al. High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. BREAST CANCER RES TR. 2004;86(3):207-213. 3.

Bibtex

@article{6fd50363553541768b02b7db6187a1c8,
title = "High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer.",
abstract = "Previous studies in small series of patients with invasive breast cancer suggested a prognostic value of Ep-CAM overexpression in primary tumor tissue. To corroborate these findings, we performed a retrospective analysis of Ep-CAM expression using a tissue microarray containing tissue specimens from a large patient set. Ep-CAM expression was evaluated by immunohistochemistry in breast cancer tissue from 1715 patients with documented raw survival data. High level Ep-CAM expression (overexpression) was found in 41.7% of tumor samples, low level expression was found in 48.0% and no expression in 10.3% of tumor samples. Ep-CAM expression predicted poor overall survival in this patient cohort (p <0.0001). Overall survival decreased significantly with increasing Ep-CAM expression. However, in this patient sample Ep-CAM expression was not an independent prognostic marker by multivariate analysis. Subgroup analysis revealed that Ep-CAM expression was a prognostic marker in node-positive (p <0.0001) but not in node-negative (p = 0.58) breast cancer patients. Intriguingly, Ep-CAM expression was predictive for a dismal prognosis in patients receiving adjuvant cytotoxic (p = 0.03) or hormonal therapy (p <0.0001) but not in untreated patients (p = 0.41). In summary, this study provides strong evidence that expression of Ep-CAM is a powerful marker of poor prognosis in node-positive invasive breast carcinoma and a potential predictive marker of sensitivity to adjuvant hormonal and/or cytotoxic treatment modalities.",
author = "Gilbert Spizzo and Philip Went and Stephan Dirnhofer and Peter Obrist and Ronald Simon and Hanspeter Spichtin and Robert Maurer and Urs Metzger and {von Castelberg}, Brida and Rahel Bart and Shanna Stopatschinskaya and K{\"o}chli, {Ossi Robert} and Philip Haas and Friedrich Mross and Markus Zuber and Holger Dietrich and Susanne Bischoff and Martina Mirlacher and Guido Sauter and Guenther Gastl",
year = "2004",
language = "Deutsch",
volume = "86",
pages = "207--213",
journal = "BREAST CANCER RES TR",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

RIS

TY - JOUR

T1 - High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer.

AU - Spizzo, Gilbert

AU - Went, Philip

AU - Dirnhofer, Stephan

AU - Obrist, Peter

AU - Simon, Ronald

AU - Spichtin, Hanspeter

AU - Maurer, Robert

AU - Metzger, Urs

AU - von Castelberg, Brida

AU - Bart, Rahel

AU - Stopatschinskaya, Shanna

AU - Köchli, Ossi Robert

AU - Haas, Philip

AU - Mross, Friedrich

AU - Zuber, Markus

AU - Dietrich, Holger

AU - Bischoff, Susanne

AU - Mirlacher, Martina

AU - Sauter, Guido

AU - Gastl, Guenther

PY - 2004

Y1 - 2004

N2 - Previous studies in small series of patients with invasive breast cancer suggested a prognostic value of Ep-CAM overexpression in primary tumor tissue. To corroborate these findings, we performed a retrospective analysis of Ep-CAM expression using a tissue microarray containing tissue specimens from a large patient set. Ep-CAM expression was evaluated by immunohistochemistry in breast cancer tissue from 1715 patients with documented raw survival data. High level Ep-CAM expression (overexpression) was found in 41.7% of tumor samples, low level expression was found in 48.0% and no expression in 10.3% of tumor samples. Ep-CAM expression predicted poor overall survival in this patient cohort (p <0.0001). Overall survival decreased significantly with increasing Ep-CAM expression. However, in this patient sample Ep-CAM expression was not an independent prognostic marker by multivariate analysis. Subgroup analysis revealed that Ep-CAM expression was a prognostic marker in node-positive (p <0.0001) but not in node-negative (p = 0.58) breast cancer patients. Intriguingly, Ep-CAM expression was predictive for a dismal prognosis in patients receiving adjuvant cytotoxic (p = 0.03) or hormonal therapy (p <0.0001) but not in untreated patients (p = 0.41). In summary, this study provides strong evidence that expression of Ep-CAM is a powerful marker of poor prognosis in node-positive invasive breast carcinoma and a potential predictive marker of sensitivity to adjuvant hormonal and/or cytotoxic treatment modalities.

AB - Previous studies in small series of patients with invasive breast cancer suggested a prognostic value of Ep-CAM overexpression in primary tumor tissue. To corroborate these findings, we performed a retrospective analysis of Ep-CAM expression using a tissue microarray containing tissue specimens from a large patient set. Ep-CAM expression was evaluated by immunohistochemistry in breast cancer tissue from 1715 patients with documented raw survival data. High level Ep-CAM expression (overexpression) was found in 41.7% of tumor samples, low level expression was found in 48.0% and no expression in 10.3% of tumor samples. Ep-CAM expression predicted poor overall survival in this patient cohort (p <0.0001). Overall survival decreased significantly with increasing Ep-CAM expression. However, in this patient sample Ep-CAM expression was not an independent prognostic marker by multivariate analysis. Subgroup analysis revealed that Ep-CAM expression was a prognostic marker in node-positive (p <0.0001) but not in node-negative (p = 0.58) breast cancer patients. Intriguingly, Ep-CAM expression was predictive for a dismal prognosis in patients receiving adjuvant cytotoxic (p = 0.03) or hormonal therapy (p <0.0001) but not in untreated patients (p = 0.41). In summary, this study provides strong evidence that expression of Ep-CAM is a powerful marker of poor prognosis in node-positive invasive breast carcinoma and a potential predictive marker of sensitivity to adjuvant hormonal and/or cytotoxic treatment modalities.

M3 - SCORING: Zeitschriftenaufsatz

VL - 86

SP - 207

EP - 213

JO - BREAST CANCER RES TR

JF - BREAST CANCER RES TR

SN - 0167-6806

IS - 3

M1 - 3

ER -